CNS Network selects ALPHADAS, Logos Technologies Early Phase EDC System


Company News Release

CNS Network has purchased ALPHADAS®, Logos Technologies Inc’s early phase, e-source data capture system and site automation tools to accelerate and streamline its clinical trials. ALPHADAS is to be implemented in their Orange County Research Center, California, USA.

“We welcome CNS Network as our most recent client partner,” said Giles Wilson, BEng, CEO of Logos Technologies Inc. “Providing real-time reporting and review to their clients and Sponsors was an important requirement and we look forward to life changing and life saving drugs reaching the market safely and more quickly.”

CNS Network is an independent research organization located in the greater Los Angeles metropolitan market. They conduct phase I-III clinical trials and specialize in early phase trials for disease populations. They are finishing construction of their 25,000 square foot, state-of-the-art facility and have decided to incorporate the ALPHADAS early phase unit automation product. They evaluated several other products in the sector and chose ALPHADAS because of its depth of product functionality and the experience of Logos Technologies.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.